Sanofi to create standalone European API production powerhouse

24 Feb 2020

Sanofi's plans to create a European company to manufacture and market active pharmaceutical ingredients (APIs) should help to balance the region's heavy reliance on sourcing them from Asian markets, the French pharmaceutical firm said Monday.

The new standalone company would combine Sanofi’s API commercial and development activities with six of its European API production sites at Brindisi (Italy), Frankfurt Chemistry (Germany), Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France).

Sanofi to create standalone European API production powerhouse

It would rank as the world's second largest API producer, employing 3,100 people and with expected sales of €1 billion by 2022.

API sourcing and the global market's dependency on China have come into sharp focus recently following the coronavirus outbreak.

“Based on the expertise and experience built over decades within our industrial network, this new entity will help ensure a greater stability in supplying drugs to millions of patients in Europe and beyond," said Philippe Luscan, Executive Vice President, Global Industrial Affairs at Sanofi. "With this endeavor, this new entity will be agile as a standalone company and able to unlock its growth potential, especially in capturing new third-party sales and all the opportunities of a market growing at a pace of 6% per year."

By operating independently, the new entity plans to increase sales to third parties and to expand partnerships with other pharmaceutical companies.

Sanofi said it boasts a broad portfolio of both volume and niche products, high standards of quality, competitive pricing, state-of-the-art industrial capabilities and technologies across Europe as well as being able to leverage a commercial network covering more than 80 countries.

Sanofi will hold a minority stake of around 30% in the new company, which it intends to be debt free. It said it would decide whether to press ahead with a planned IPO on Euronext Paris by 2022, subject to market conditions.

Read More

Companies mentioned

Related tags

Market News

Related news

UPDATED: COVID-19 PHARMA TRACKER

UPDATED: COVID-19 PHARMA TRACKER

3 Apr 2020

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain…

Read more 
Chinese CDMOs legislating for the future

Chinese CDMOs legislating for the future

2 Apr 2020

The Chinese pharmaceutical CDMO sector is set for rapid expansion, thanks to major amendments to the country's Drug Administration Law that make outsourcing manufacturing easier

Read more 
FDA orders ranitidine withdrawal due to nitrosamine contamination risk

FDA orders ranitidine withdrawal due to nitrosamine contamination risk

2 Apr 2020

US drug regulator, the Food and Drug Administration has ordered the immediate withdrawal of all prescription and over-the-counter versions of heartburn drug, ranitidine – commonly known as Zantac – after concluding certain products may present an incre...

Read more 
China focused on meeting international API demand amid pandemic, say officials

China focused on meeting international API demand amid pandemic, say officials

1 Apr 2020

China is stepping up its efforts to produce and ship active pharmaceutical ingredients (APIs), with a focus on meeting international demand, particularly for those showing potential to treat the COVID-19 disease, according to Chinese officials on Tuesd...

Read more 
New blood test able to detect 50 cancer types

New blood test able to detect 50 cancer types

31 Mar 2020

Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.

Read more 
Cambrex names Troy Player as head of early stage development and testing

Cambrex names Troy Player as head of early stage development and testing

31 Mar 2020

Cambrex has appointed pharma industry veteran, Troy Player, as president, early stage development and testing, the contract development and manufacturing organisation said Tuesday.

Read more 
CDMO Ritedose chooses ChargePoint to ensure drug substance mixing process sterility

CDMO Ritedose chooses ChargePoint to ensure drug substance mixing process sterility

31 Mar 2020

The Ritedose Corporation, a contract development and manufacturing organisation (CDMO) with a focus on inhalation and ophthalmic products, has partnered with ChargePoint Technology to ensure the sterility of its drug substance mixing process.

Read more 
EMA to only issue electronic medicines certificates during COVID-19 pandemic

EMA to only issue electronic medicines certificates during COVID-19 pandemic

30 Mar 2020

The European Medicines Agency (EMA) said Monday it will only issue electronically signed and authenticated certificates for human and veterinary medicines in place of printed ones so it can continue to provide the documents during the COVID-19 pandemic...

Read more 
PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?

PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?

30 Mar 2020

Joint venture between Spinview and VR Media Technology creates device that provides accurate and fast detection of infectious people with far greater clarity than any single parameter test available today.

Read more 
New device offers a convenient way to monitor compressed air for viable particles

New device offers a convenient way to monitor compressed air for viable particles

30 Mar 2020

Specialist cleanroom microbiology solutions company offers the new SAS Super Pinocchio CR compressed air sampling device.

Read more